Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Enoby (RGB-14-P) vs Prolia in Postmenopausal Osteoporosis
NCT05087030Phase 3Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of HS629 in postmenopausal osteoporosis (5 arms), sponsored by Gedeon Richter Plc. Primary endpoints: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density at Week 52 and Area Under the Effective Curve of %CfB in Serum Type I Collagen C-telopeptide at Week 26. Started Sep 2021; status: completed.
02
Drugs
HS629
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT05087030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087030.